ALSN vs RGEN
ALSN: Allison Transmission is the global leader in fully automatic transmissions for medium- and heavy-duty commercial and defense vehicles. RGEN: Repligen provides innovative bioprocessing technologies and systems that enhance the efficiency and flexibility of manufacturing biological drugs, including mAbs, vaccines, and cell therapies.
Side-by-side fundamentals
| Metric | ALSN | RGEN | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $108.05 | $176.94 | |
| Market cap | $8.9B | $10.0B | |
| P/E as of 2026-10-30 | 17.10 | n/a | |
| PEG as of 2026-10-30, 3-year EPS CAGR to FY2025 | 1.74 | n/a | |
| Net margin FY2025, SEC XBRL | +20.7% | n/a | |
| Gross margin FY2025, SEC XBRL | +48.6% | n/a | |
| Operating margin FY2025, SEC XBRL | +29.2% | n/a | |
| ROE FY2025, SEC XBRL | +33.4% | +2.3% | ALSN higher |
| ROA FY2025, SEC XBRL | +10.2% | +1.7% | ALSN higher |
| Debt / equity | 2.07 | 0.27 | RGEN lower |
| Revenue growth (YoY) FY2025, SEC XBRL | -6.7% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +2.8% | +30.5% | RGEN higher |
| Dividend yield as of 2026-09-03 | 1.07% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ALSN higher |
| Beta as of 2026-09-03 | 1.06 | 1.40 | |
| 1-year return as of 2026-10-30 close | +29.3% | +22.4% | ALSN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.